TP53 and pancreatic neoplasm: Variations in the mutations in pancreatic cancer are relatively low, and the major driver mutations are known as “the big four,” namely, KRAS, TP53, CDKN2A, SMAD4, which are present in most (50–95%) pancreatic cancer patients.